ClinicalTrials.gg
CompletedNCT00661778Updated Jul 10, 2014Results posted

A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

A Phase 2 interventional study of Bevacizumab and Cisplatin in Non-small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 14 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-10.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 15 under way, 3 of them phase 3. Bevacizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
78th of 149
50 · median 56
Started
2007
with 11 others
Phase 2
95 of 150
6 open now
Registered
50th of 150
by date
Lead sponsor
10 of 150
Hoffmann-La Roche

Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, this one is the 78th largest by enrollment of the 149 interventional ones that give a count, is one of 12 that started in 2007, is one of 95 in phase 2, and was the 50th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m\^2, and cisplatin 75 mg/m\^2 on Day 1 of each 3-week cycle for a maximum of 6 cycles.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥ 18 years of age.
  • Stage IIIb or IV non-small cell lung cancer.
  • Chemotherapy-naive.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment for non-small cell lung cancer.
  • Previous malignant tumor within last 5 years, except for basal cell skin cancer or preinvasive cervical cancer.
  • Major surgical procedure, open , or significant traumatic injury within 28 days prior to start of study.
  • Recent or current chronic treatment with aspirin (> 325 mg/day).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Bevacizumab + cisplatin + docetaxel

    Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m\^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.

    Drug: Bevacizumab · Drug: Cisplatin · Drug: Docetaxel

Interventions

  • Bevacizumab was supplied as a sterile liquid in glass vials.

    Also known as: Avastin

  • Bevacizumab was supplied as a sterile liquid in glass vials.

  • Bevacizumab was supplied as a sterile liquid in glass vials.

    Also known as: Taxotere

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.

    Time frame: Baseline to the end of the study (up to 4 years)

Secondary outcomes

  1. Percentage of Participants With an Objective Response

    An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.

    Time frame: Baseline to the end of the study (up to 4 years)

  2. Duration of the Objective Response

    Duration of the objective response is defined as the time from a complete or partial response to disease progression or death due to disease.

    Time frame: Baseline to the end of the study (up to 4 years)

  3. Overall Survival

    Overall survival is defined as the time from the first dose of study medication until death.

    Time frame: Baseline to the end of the study (up to 4 years)

  4. 1-year Survival

    The probability of surviving 1 year was estimated using the Kaplan-Meier method.

    Time frame: Baseline to 1 year

07

Results

Posted Jul 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + Cisplatin + Docetaxel
Started50
Completed0
Not completed50
Withdrew: Disease progression23
Withdrew: Adverse event18
Withdrew: Reason not specified6
Withdrew: Protocol violation2
Withdrew: Withdrawal of consent1

Outcome measures

PrimaryProgression-free Survival

Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.

Time frame:
Baseline to the end of the study (up to 4 years)
Reported as:
Median · Months
Progression-free Survival
MonthsBevacizumab + Cisplatin + Docetaxel
Progression-free Survival8.95 (6.92 to 9.97)
SecondaryPercentage of Participants With an Objective Response

An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.

Time frame:
Baseline to the end of the study (up to 4 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With an Objective Response
Percentage of participantsBevacizumab + Cisplatin + Docetaxel
Percentage of Participants With an Objective Response67.39
SecondaryDuration of the Objective Response

Duration of the objective response is defined as the time from a complete or partial response to disease progression or death due to disease.

Time frame:
Baseline to the end of the study (up to 4 years)

Results for this outcome have not been posted.

SecondaryOverall Survival

Overall survival is defined as the time from the first dose of study medication until death.

Time frame:
Baseline to the end of the study (up to 4 years)
Reported as:
Median · Months
Overall Survival
MonthsBevacizumab + Cisplatin + Docetaxel
Overall Survival12.74 (9.48 to 17.79)
Secondary1-year Survival

The probability of surviving 1 year was estimated using the Kaplan-Meier method.

Time frame:
Baseline to 1 year
Reported as:
Number · Percentage of participants
1-year Survival
Percentage of participantsBevacizumab + Cisplatin + Docetaxel
1-year Survival53.46 (39.19 to 67.45)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Cisplatin + Docetaxel—26/49 (53.1%)48/49 (98%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventBevacizumab + Cisplatin + Docetaxel
Neutrophil count increasedInvestigations6/49
Febrile neutropeniaBlood and lymphatic system disorders5/49
PyrexiaGeneral disorders3/49
DyspneaRespiratory, thoracic and mediastinal disorders3/49
Respiratory tract infectionInfections and infestations2/49
DiarrhoeaGastrointestinal disorders2/49
Mucosal inflammationGeneral disorders2/49
HaemoptysisRespiratory, thoracic and mediastinal disorders2/49
Positron emission tomographyInvestigations1/49
Decreased leukocyte countInvestigations1/49
Most frequent other events
Showing 10 of 152
Most frequent other events
EventBevacizumab + Cisplatin + Docetaxel
FatigueGeneral disorders36/49
DiarrhoeaGastrointestinal disorders27/49
AlopeciaSkin and subcutaneous tissue disorders22/49
Decreased hemoglobinInvestigations21/49
Mucosal inflammationGeneral disorders21/49
NauseaGastrointestinal disorders19/49
EpistaxisRespiratory, thoracic and mediastinal disorders19/49
VomitingGastrointestinal disorders18/49
AnorexiaMetabolism and nutrition disorders17/49
PyrexiaGeneral disorders15/49

Baseline characteristics

Intent-to-treat population: All enrolled participants who received at least 1 treatment.

Age, Continuous
Age, Continuous(Years)Bevacizumab + Cisplatin + Docetaxel
Mean58.31 ± 9.54
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + Cisplatin + Docetaxel
Female12
Male38
08

Study locations

14 sites
  • Cádiz, Cadiz 11009, Spain
  • San Sebastian, Guipuzcoa 20080, Spain
  • Palma de Mallorca, Islas Baleares 07198, Spain
  • Alcala de Henares, Madrid 28805, Spain
  • Sagunto, Valencia 46520, Spain
  • Castellon, 12002, Spain
  • Madrid, 28036, Spain
  • Madrid, 28935, Spain
  • Malaga, 29010, Spain
  • Palencia, 34005, Spain
  • Valencia, 46017, Spain
  • Valladolid, 47005, Spain
  • Valladolid, 47010, Spain
  • Zamora, 49021, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2008
First posted
Apr 18, 2008
Start
Jul 2007
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Jul 10, 2014
Last update
Jul 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00661778
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 18, 2008
Start date
Jul 2007
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Jul 10, 2014
Last update
Jul 10, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Cisplatin · Docetaxel

Start the discussion